Raffaele Colombo
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Raffaele Colombo
Jul 18, 2024, 09:52 |
Insight
Raffaele Colombo: Trastuzumab rezetecan in patients with HER2-mutant NSCLC
Raffaele Colombo shared a post on X about a recent paper by Shun Lu et…
Jul 15, 2024, 08:52 |
Blog
Raffaele Colombo: Tisotumab vedotin as 2nd or 3rd line therapy for recurrent cervical cancer
Raffaele Colombo shared a post on X about recent paper by Ignace Vergote et al.…
Jul 3, 2024, 08:52 |
Insight
Paolo Tarantino: More data supporting that ADCs act in part by extending the half life of payloads
Paolo Tarantino shared a post by Raffaele Colombo on X, adding the following: “More data…
Jul 1, 2024, 07:57 |
Blog
Raffaele Colombo: TOPO1i ADC after TOPO1i ADC?
Raffaele Colombo shared on X: "TOPO1i ADC after TOPO1i ADC? ADC-LOW: a French, multicentric, retrospective study…
Jun 25, 2024, 16:01 |
Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X: . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
May 26, 2024, 10:23 |
Insight
Raffaele Colombo: We always learn a lot from the publications of “unsuccessful” trials
Raffaele Colombo shared on X/Twitter: "We always learn a lot from the publications of 'unsuccessful' trials.…
May 13, 2024, 14:12 |
Blog
Raffaele Colombo: Personal selection of 30 new ADCs that will be presented at ASCO24
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on X: "Personal selection of…
Apr 9, 2024, 12:53 |
Blog
Christiana Bardon: The AACR industry partnering event was a tremendous success
Christiana Bardon, Co-Managing Partner at MPM BioImpact, shared on their LinkedIn: ''The American Association for…
Apr 8, 2024, 15:15 |
Blog
Raffaele Colombo: AACR Annual Meeting 2024 has started!
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on LinkedIn: "AACR Annual Meeting…
Mar 21, 2024, 17:13 |
Blog
Raffaele Colombo: It was such an honor and a pleasure to open the DAVA Oncology Think Tank on Antibody Drug Conjugates and Bispecifics meeting in Victoria
Raffaele Colombo, Principal Scientist and Group Lead, Medicinal Chemistry at Zymeworks Inc., recently posted on…
Feb 22, 2024, 18:56 |
Blog
Raffaele Colombo: Application based on results from the TROPION-Lung01 phase 3 trial
Raffaele Colombo, Principal Scientist & Group Lead, Medicinal Chemistry at Zymeworks, shared on X/Twitter: "Application based…
Jan 24, 2024, 22:30 |
Insight
Raffaele Colombo: Evoke-01 study of sacituzumab govitecan (SG) did not meet its primary overall survival goal in patients with NSCLC
Raffaele Colombo, Principal Scientist at Zymeworks, shared on X: "Evoke-01 study of sacituzumab govitecan (SG)…
Nov 15, 2023, 17:08 |
History
Raffaele Colombo: Can you believe these were written almost 40 years ago?
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute shared a post on Twitter by…
Nov 4, 2023, 00:58 |
Drugs
Raffaele Colombo: Here the breakdown of the Monomethyl auristatin E Antibody Drug Conjugates
Raffaele Colombo, Principal Scientist at Zymeworks, shared on X/Twitter: 106 auristatin Antibody Drug Conjugates (ADCs)…
Oct 16, 2023, 23:06 |
Opinion
Paolo Tarantino: Greatly enjoyed contributing to the ADC session at Targets23!
Paolo Tarantino, MD and Researcher at the European Institute of Oncology and Clinical Research Fellow at…
Oct 14, 2023, 22:16 |
Blog
Paolo Tarantino: So much going on in the ADC field.
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared the following on Twitter: "So…
Oct 10, 2023, 00:45 |
Blog
Raffaele Colombo: Remember the days of meeting handouts? And having all the ADCs summarized in one page?
Raffaele Colombo, Principal Scientist and Group Lead, Medicinal Chemistry at Zymeworks Inc., made the following post…
Oct 2, 2023, 22:37 |
Insight
Paolo Tarantino: Antibody drug conjugates (ADCs) are leading to relevant survival improvements for multiple types of cancer.
Paolo Tarantino, MD and researcher at the European Institute of Oncology and clinical research fellow…
Oct 2, 2023, 18:10 |
Insight
Raffaele Colombo: ADC history.
Quoting Raffaele Colombo, Principal Scientists at Zyme Works on X/Twitter: “Maytansine was isolated in the…
Aug 14, 2023, 17:26 |
Insight
Raffaele Colombo: WHO INN proposed list 129 is out.
In a Twitter post by Raffaele Colombo, Principal Scientist at Zymeworks Inc, it says: ''WHO…
All:
20
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube